MAO-B inhibitor
Monoamine oxidase B inhibitor
- If BBB-crossing: ↑ brain dopamine → ↓ parkinsonian motor symptoms
- MAO-B selectivity is lost at higher exposure → dietary/drug interaction risk returns
- Raises dopamine — used in Parkinson disease
- Selectivity is lost at higher doses, bringing MAO-A risks with it
Drugs with this mechanism (14)
- Isocarboxazid — Rarely used irreversible MAOI.
- Isoniazid — First-line tuberculosis drug; hepatotoxicity and pyridoxine-responsive neuropathy shape use.
- Linezolid — Oxazolidinone antibiotic for resistant gram-positives; a reversible MAOI (serotonin risk).
- Methylene blue — Methemoglobinemia antidote and potent MAOI; serotonergic combinations can be dangerous.
- Moclobemide — Reversible MAO-A inhibitor (RIMA); safer tyramine profile; not marketed in the US.
- Phenelzine — Irreversible, nonselective MAOI for atypical or resistant depression; tyramine restrictions apply.
- Procarbazine — DNA-damaging chemotherapy used in lymphoma and brain-tumor regimens; weak MAO inhibition adds food and drug interaction concerns.
- Rasagiline — Selective MAO-B inhibitor for Parkinson; no tyramine diet at usual dose.
- Safinamide — Reversible MAO-B inhibitor added to levodopa for Parkinson wearing-off; can worsen dyskinesia and has important serotonergic interactions.
- Selegiline — MAO-B-selective at low dose; the transdermal patch treats depression without diet at low strength.
- Selegiline transdermal — MAOI antidepressant patch; the 6 mg/24 h dose needs no tyramine diet, sparing gut MAO-A.
- Tedizolid — Once-daily oxazolidinone for acute bacterial skin infections, including MRSA; inhibits 50S protein synthesis.
- Tranylcypromine — Activating, amphetamine-like MAOI; dietary restrictions apply.
- Zonisamide — Broad anticonvulsant associated with weight loss.
All mechanisms · Open MAO-B inhibitor in the interactive console ↗